Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03944772 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)
A Phase 2 study of Non-Small Cell Lung Cancer, sponsored by AstraZeneca.
- Active
- Registry status
- Phase 2
- Development phase
- 247
- Enrollment target
- 20
- Study locations
NCT03944772 is a Phase 2 study of Non-Small Cell Lung Cancer that is active but no longer recruiting, run by AstraZeneca. The registered enrollment target is 247 participants, below the 658-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (62% lower). The trial reports 20 study locations across 12 states.
The verdict
NCT03944772, a Phase 2 study of Non-Small Cell Lung Cancer, is active but no longer recruiting, sponsored by AstraZeneca.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 247 participants
- Enrollment target
- 20
- Study locations
Study Summary
Phase 2 Platform Study in Patients with Advanced Non-Small Lung Cancer who progressed on First-Line Osimertinib Therapy. This study is modular in design, allowing evaluation of the efficacy, safety and tolerability of multiple study treatments.
Conditions Studied
Interventions
- DRUG Osimertinib
- DRUG Durvalumab
- DRUG Gefitinib
- DRUG Savolitinib
- DRUG Necitumumab
Study Locations (20)
California
- Research Site - Duarte
- Research Site - Los Angeles
- Research Site - Sacramento
- Research Site - Santa Monica
Other
- Research Site - Odense C
- Research Site - Catania
- Research Site - Naples
- Research Site - Orbassano
Massachusetts
- Research Site - Boston
- Research Site - Boston
New York
- Research Site - New York
- Research Site - New York
Connecticut
- Research Site - New Haven
Illinois
- Research Site - Chicago
Maryland
- Research Site - Baltimore
Michigan
- Research Site - Grand Rapids
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 247 participants |
| Start Date | 2019-06-25 |
| Est. Completion | 2025-05-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03944772
The ClinicalTrials.gov registry entry for NCT03944772 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 247 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 658-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (62% lower). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 5 interventions - of which Osimertinib is the first listed.
NCT03944772 reports 20 study locations spanning 12 distinct geographic areas - top geographies include California, Other, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT03944772 about?
NCT03944772 is a clinical study titled "Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)". Phase 2 Platform Study in Patients with Advanced Non-Small Lung Cancer who progressed on First-Line Osimertinib Therapy. This study is modular in design, allowing evaluation of the efficacy, safety and tolerability of multiple study treatments.
What is the current status of trial NCT03944772?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 247 participants. The study started on 2019-06-25. Estimated completion is 2025-05-06.
What conditions does trial NCT03944772 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer.
What interventions are being tested in trial NCT03944772?
The interventions under investigation include: Osimertinib (DRUG), Durvalumab (DRUG), Gefitinib (DRUG), Savolitinib (DRUG), Necitumumab (DRUG).
Who is sponsoring clinical trial NCT03944772?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03944772 being conducted?
This trial has 20 study locations across California, Connecticut, Illinois, Maryland, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
RECRUITING · Phase 2
-
Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
RECRUITING · Phase 2
-
A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.